Tandem Mobi uses an advanced hybrid closed-loop automated insulin delivery feature that helps in anticipating and preventing fluctuations in blood sugar levels
Tandem Diabetes announces commercial launch of the Tandem Mobi automatic insulin delivery system in the US. (Credit: Business Wire)
Tandem Diabetes Care, an American company specialising in insulin delivery and diabetes technology, has announced the commercial launch of its latest product, Tandem Mobi, in the US.
Tandem Mobi is a compact and robust automated insulin delivery system designed for individuals with diabetes.
According to Tandem Diabetes Care, orders for the system are now being accepted and shipments are underway to eligible customers across the US. The commercial launch follows the clearance from the US Food and Drug Administration (FDA) for Tandem Mobi in July 2023.
Tandem Mobi is said to introduce a new approach for individuals living with diabetes to benefit from the transformative features of Control-IQ technology.
Approved for individuals with type 1 diabetes aged six years and above, the advanced hybrid closed-loop automated insulin delivery feature helps in anticipating and preventing fluctuations in blood sugar levels. This results in enhanced time spent within the target range throughout the day and night, as demonstrated by various controlled clinical trials and real-world studies, said the company.
Tandem Diabetes Care president and CEO John Sheridan said: “This tiny, wearable pump exceeded the expectations of users from an early access programme, and we are thrilled to begin offering this exciting new technology to more people in the diabetes community.
“With this launch, we are executing on our strategy to offer a differentiated portfolio of durable insulin pumps, providing choice, along with new options in wearability.”
Tandem Mobi is less than half the size of the t:slim X2 insulin pump and compact enough to fit in the coin pocket of a pair of jeans. It is said to offer users greater discretion, comfort, and flexibility in diabetes management.
The insulin delivery system is compatible with all existing Tandem-branded infusion sets, including a new 5inch tubing option specifically designed for Tandem Mobi, providing over 30 mix-and-match infusion site and tubing length combinations for user convenience.
The associated mobile app offers full iOS mobile control through a user’s compatible iPhone.
Tandem Mobi is compatible with the Dexcom G6 continuous glucose monitoring (CGM) system, with plans for additional CGM sensor integrations. These include Dexcom G7 in Q2 2024 and integration with the Abbott FreeStyle Libre 3 sensor.
The Tandem Mobi system features a physical button for insulin bolus delivery without requiring an iPhone, and it utilises modern wireless charging technology while also supporting remote software updates.